

# Adjuvant

HER2 +

HER2 -

Triple Negative

ER +

**[ECOG-ACRIN-A011801](#)**  
[Phase III T-DM1 & Placebo Compared with T-DM1 & Tucatinib - COMPASSHER2](#)

PI: Telli  
Sponsor: ECOG-ACRIN

**[BRS0141](#)**  
[FLAMINGO-01 Phase III HER2/Neu Peptide GLSI-100 \(GP2 + GM-CSF\) in HER2/Neu Positive Subjects with Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy](#)

PI: Riaz  
Sponsor: Greenwich LifeSciences, Inc.

**[NRGBR008](#)**  
[Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer - HER2 Radiation Optimization \(HERO\)](#)

PI: Wapnir  
Sponsor: NRG

**[ECOG-ACRIN-A012103](#)**  
[OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy w/ Checkpoint Inhibitor Therapy](#)

PI: Telli  
Sponsor: ECOG-ACRIN or Alliance? TBD.

**[BRS0121](#)**  
[Phase II Circulating Tumor DNA Monitoring During Adjuvant Capecitabine in Triple-Neg Breast Cancer](#)

PI: Telli  
Sponsor: Stanford University

**[BRS0146](#)**  
[CAMBRIA-1: Phase III Extended Therapy w/ Camizestrant \(AZD9833\) vs Standard Endocrine Therapy \(Aromatase Inhibitor or Tamoxifen\) in ER+/HER2- Early Breast Cancer and Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy & at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence](#)

PI: Telli  
Sponsor: AstraZeneca

**[NRGBR007](#)**  
[Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer](#)

PI: Wapnir  
Sponsor: NRG

**KEY**

- Pending
- Open for Enrollment
- Observational Study
- Enrollment on Hold
- Optional Path
- Link Trial Posting
- Extension Study
- Immunotherapy